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Indirect morbidity and mortalityBackground: The international healthcare response to COVID-19 has been driven by epidemiological data
related to case numbers and case fatality rate. Second order effects have been less well studied. This study
aimed to characterise the changes in emergency activity of a high-volume cardiac catheterisation centre
and to cautiously model any excess indirect morbidity and mortality.
Method: Retrospective cohort study of patients admitted with acute coronary syndrome fulfilling criteria
for the heart attack centre (HAC) pathway at St. Bartholomew’s hospital, UK. Electronic data were col-
lected for the study period March 16th – May 16th 2020 inclusive and stored on a dedicated research ser-
ver. Standard governance procedures were observed in line with the British Cardiovascular Intervention
Society audit.
Results: There was a 28% fall in the number of primary percutaneous coronary interventions (PCIs) for ST
elevation myocardial infarction (STEMI) during the study period (111 vs. 154) and 36% fewer activations
of the HAC pathway (312 vs. 485), compared to the same time period averaged across three preceding
years. In the context of ‘missing STEMIs’, the excess harm attributable to COVID-19 could result in an
absolute increase of 1.3% in mortality, 1.9% in nonfatal MI and 4.5% in recurrent ischemia.
Conclusions: The emergency activity of a high-volume PCI centre was significantly reduced for STEMI
during the peak of the first wave of COVID-19. Our data can be used as an exemplar to help future mod-
elling within cardiovascular workstreams to refine aggregate estimates of the impact of COVID-19 and
inform targeted policy action.
 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As of June 18th 2020 there have been over 400,000 deaths
and>8 million cases of COVID-19 worldwide.[1] Healthcare policy
has varied considerably and many unknowns remain regarding
the virus – an accurate measure of its prevalence; the size, scale
and timing of a second peak of infections; and the efficacy of treat-
ments currently being tested, including a vaccine.
As COVID-19 becomes an increasing economic and societal
problem, communication of its wider effects – including indirect
consequences to healthcare – will have a growing impact on set-
ting both national and international policy. A recent model pub-lished in the UK sought to estimate the excess 1 year mortality
under a number of assumptions.[2] The use of granular data from
specific disease and treatment pathways has been an underutilised
resource so far in helping to shape aggregate models which policy
makers use to determine the pandemic response.
We report the changes in emergency activity at our high-
volume cardiac centre, examining the number of primary percuta-
neous coronary interventions (primary PCIs) for ST-segment eleva-
tion myocardial infarction (STEMI) and the total number of
activations of our heart attack centre (HAC) pathway. Relevant
characteristics of STEMI cases, including measures of system
activity such as number of patients thrombolysed and door to bal-
loon (DTB) time were also analysed. We additionally model the
excess indirect morbidity and mortality of service reconfigurations
under a number of pragmatic assumptions.
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A service evaluation of catheter lab activity at St Bartholomew’s
Hospital (SBH) was registered with the Clinical Effectiveness Unit
on May 1st, 2020, (Project ID 11152). Anonymous data were retro-
spectively extracted as part of the usual governance processes
observed for the British Cardiovascular Intervention Society
national angioplasty audit [3], and quality assurance processes
were followed according to protocols used by the audit department
at SBH. The number of activations of the HAC pathway was exam-
ined and the characteristics of patients coded as having a STEMI
were analysed. MI was defined according to the Fourth Universal
Definition of Acute [4]. Data was collected during a two month per-
iod – March 16th- May 16th 2020, which covered the peak of cases
in the UK during the first wave of the COVID19 pandemic.
All patients who were admitted as a suspected STEMI to St.
Bartholomew’s hospital under the HAC pathway were eligible for
inclusion [Box 1]. Admissions were compared with the average
number of STEMIs and HAC activations over the same time period
in the previous three years. There was no data loss. Estimation of
the excess indirect morbidity and mortality of different strategies
was based on absolute risk increases from pooled RCT data [5] –
for example, in terms of mortality, this was 7% after PPCI versus
9% after thrombolysis (p = 0.0002) and this method has been inde-
pendently used by another group [6].
Clinical, demographic, and procedural characteristics are sum-
marised using percentages or means and standard deviations as
appropriate and compared using one-way analysis of variance
(ANOVA) for continuous variables (expressed as mean ± standard
deviation) and the v2 tests or the Fisher’s exact tests for categorical
variables (expressed as count and percentage). The statistical soft-
ware programme SPSS version 24 was used. The manuscript has
been prepared according to The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) Statement [7].2.1. Patient and public involvement
There was no patient or public involvement during the course of
this study.3. Results
During the study period, 111 STEMIs were treated with primary
PCI and 135 angiograms were performed in total. Over an average
of the same time period across the preceding three years, there
were 154 STEMIs treated with primary PCI and 243 angiograms
performed. This represents a 28% fall in primary PCI activity for
STEMI. The total number HAC activations was 312, compared to
485 activations across the same time period over the preceding
three years, representing a 36% fall in activity, highlighted in
Fig. 1. The ratio of primary PCI for STEMI as a proportion of total
HAC activations is shown in Fig. 2. The average number of HAC
activations a week in 2020 was 26 with 11 undergoing primary
PCI per week. In comparison to the same period in 2019, there
were 42 activations on average per week with 13 undergoing pri-
mary PCI per week.
When evaluating the characteristics of the STEMI cases, 2020
data was compared directly to 2019.
The baseline characteristics of the patients treated were similar
and both mean Door To Balloon (DTB) time (50mins vs. 51mins
(p = 0.32)), and call to balloon time (241mins vs. 194mins
(p = 0.08)) were not statistically different (Table 1). There was a
trend toward poorer outcomes with respect to left ventricular
function – the proportion of patients coded as severe LV impair-
ment (EF < 35%) was 12.6% during the study period vs. 7.7%2
(p = 0.8) in the same period in 2019. The rate of LV thrombus in
patients with STEMI was 7.2% during the study period, compared
to 4.5% (p = 0.1). The total number of patients thrombolysed during
the study period was two (0.6%), compared to none in the previous
year. Table 2.
3.1. Estimated excess indirect morbidity and mortality
Over the study period, we have cautiously modelled for the fol-
lowing indirect effects of COVID-19 using a series of pragmatic
assumptions:
Scenario A: assume 43 missing STEMI patients were treated
with fibrinolysis rather than primary PCI. Using the meta-analysis
by Keeley et al. [5], this would cause an additional harm at 30 days
of one extra death, three non-fatal MIs, seven episodes of recurrent
ischemia, and up to one extra stroke.
Scenario B: same as Scenario A but assume treatment was with
medical therapy only, rather than primary PCI. One extra death in
addition to Scenario A would be incurred – using data from the
original fibrinolysis versus medical care RCTs.[8] For our sample,
this would represent an absolute increase of 1.3% in mortality,
1.9% in nonfatal MI, 4.5% in recurrent ischemia, and 0.6% increase
in stroke.
Scenario C: assume Scenario A or B plus an additional burden of
an absolute increase of 5% of STEMI patients presenting with sev-
ere LV impairment and 2.5% absolute increase in patients with
LV thrombus.4. Discussion
This report examines the changes in activity and experiences at
a high volume cardiac centre and the possible downstream conse-
quences for patients. We highlight three key messages:
1. The overall number of patients treated with primary PCI for
STEMI was significantly reduced over a two-month period, with
a larger associated fall in activations of our HAC pathway.
2. Very few patients were treated with thrombolysis during this
study period, in spite of pragmatic advice recommended by
many internationally respected sources.
3. The indirect excess harm is difficult to approximate and extrap-
olate to a national setting. The annual UK number of STEMI
cases is approximately 35,000[9] – allowing for small monthly
variations, a reasonable estimate of 6000 STEMIs would occur
in two months in non-COVID times. If the reduction of activity
was similar across all primary PCI centres – and evidence sup-
ports this from other UK centres [10] – then almost 1700 STEMI
cases would be missing, which may represent 80 extra deaths,
120 non-fatal MIs and 280 episodes of recurrent ischaemia
and 40 S. There may also be an additional 255 patients who
have severe LV impairment and 162 patients with LV thrombus.
5. Comparison with other studies
Another UK centre has examined the possible delays to primary
PCI over a one month period, using a surrogate of time to first med-
ical contact (FMC) to approximate any changes in patient beha-
viour. The delay in symptom-to-FMC was significantly longer
(227 [65–790] vs.119 [27–203] min, P = 0.01) and in 26.1% of the
cohort the time from symptom to FMC was >12 h [10]. Nationally,
recent summary level data published after the first wave of the
pandemic demonstrated a 43% decline in primary PCI rates for
STEMI, an increased median call to arrival time of 15 min with a
non-statistically significant difference in in-hospital mortality of
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Fig. 1. Weekly trend of HAC activations over study period (Blue line) versus trend across three year average between 2017 and 2019. (For interpretation of the references to
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Fig. 2. Ratio of HAC activations versus primary PCI in 2019 and 2020.
Table 1
Baseline Characteristics of STEMI patients who underwent primary PCI. Abbrevia-
tions: ACS = Acute Coronary Syndrome, MI = Myocardial Infarction, CABG = Coronary
Artery bypass grafting, MV = Multi-vessel, PVD = Peripheral Vascular disease,
CKD = Chronic Kidney disease, LV = Left ventricular, CVA = Cerebrovascular accident,
OOHA = Out of hospital cardiac arrest.
2019 2020 p Value
(n = 155) (n = 111)
Age (yrs) 61.33 ± 14.22 61.35 ± 13.20 0.361
Ethnicity (Asian) 51 (32.9%) 32 (28.8%) 0.284
Gender (Male) 110 (71.0%) 82 (73.9%) 0.352
Previous MI 23 (14.8%) 13 (11.7%) 0.292
Previous PCI 22 (14.2%) 15 (13.5%) 0.511
Previous CABG 5 (3.2%) 1 (0.9%) 0.204
Hypercholesterolaemia 67 (43.2%) 46 (41.4%) 0.435
Diabetes mellitus 44 (28.4%) 34 (30.6%) 0.396
Hypertension 70 (45.1%) 56 (50.5%) 0.233
Smoking History 69 (44.5%) 49 (44.1%) 0.526
PVD 1 (0.6%) 3 (2.7%) 0.198
CKD (Creatinine > 200) 2 (1.3%) 1 (0.9%) 0.623
Previous CVA 3 (1.9%) 2 (1.8%) 0.653
Poor LV function 12 (7.7%) 14 (12.6%) 0.822
Cardiogenic Shock 9 (5.8%) 10 (9%) 0.223
OOHCA 11 (7.1%) 2 (1.8%) 0.041
Table 2








Radial 133 (85.8%) 102 (91.9%) 0.090
Median Door to Balloon
Times
51 mins ± 54 (SD) 50 mins ± 100
(SD)
0.318
Median Call to Balloon
Times
194 mins ± 228
(SD)
241 mins ± 282
(SD)
0.081
LV thrombus rates 7 (4.5%) 8 (7.2%) 0.107
GP IIb/IIIa inhibitor 48 (31.0%) 51 (45.9%) 0.009
TIMI Flow Pre-Procedure
(0)
65 (41.9%) 51 (45.9%) 0.300
Procedural Success 94 (60.6%) 75 (67.6%) 0.152
Y. Chen, K.S. Rathod, S. Hamshere et al. IJC Heart & Vasculature 33 (2021) 100736increase in the mean call to balloon time of 47 min though this was
not statistically significant. Internationally, a multicentre, nation-
wide survey in Italy [12] observed a 48.4% reduction in admissions3
for acute myocardial infarction (AMI) throughout a 1 week period
during the COVID-19 outbreak, compared with the equivalent
week in 2019, of which STEMI was reduced by 26.5%.
Other research groups have attempted modelling of the possi-
ble increased mortality and bed occupancy incurred by a
thrombolysis-only strategy, though caution should be exercised
in direct comparisons. For instance, a time horizon of one year
rather than thirty days was employed and the numbers of patients
thrombolysed in real world clinical practice have been negligible
[12]. In addition, the breadth of different subgroups is important
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out of hospital cardiac arrest (OHCA) admissions at a national level
revealed an increased proportion of OHCA during the pandemic
period of 2%. Across a 3 month period, this translated to approxi-
mately 400 extra OHCA admissions undergoing PCI [13].5.1. Comparison with professional guidelines
A consensus statement from the American College of Cardiology
[14] and guidance from the European Society of Cardiology [15]
both emphasise the importance of maintaining primary PCI as
standard of care. This is reflected in the UK BCIS position and
advice from NHS England which additionally emphasised caution
in reflex decisions particularly around the implications of throm-
bolysis and downstream effects – this is reflected in our own num-
bers [16,17].6. Limitations
This is a single centre, retrospective study with a modest sam-
ple size. No causal inferences may be drawn as to why the levels
of primary PCI for STEMI decreased. Our assumptions regarding
the excess indirect morbidity and mortality are based on signifi-
cant caveats, primarily around
i) Assuming that there would have been an extra 43 patients in
non-COVID times and attributing excess indirect harm solely
to not receiving primary PCI
ii) Using historical data that has a different baseline event rate
to current practice
iii) Attributing trends in left ventricular function to COVID-19
and delayed treatment with primary PCI iv) assuming that
our single centre is representative of the entire UK
population.
We have also focused our analysis on STEMIs in this paper and
further work examining the activity and characteristics of patients
coded as NSTEMIs represent an important patient group to evalu-
ate. Other recently published work examined this at a national
level in the UK, demonstrating an increased mortality for NSTEMI
patients at 30 days [18]. Additionally, at our own centre, we have
published data on ancillairy cardiovascular harms due to COVID-
19, including higher multivessel thrombus burden and longer
length of stay in the subset of STEMI patients who were COVID-
19 positive [19]. Therefore consideration of this and other factors
will allow more precise modelling of the totality of second order
harms related to the COVID-19 pandemic and its impact on
patients with acute coronary syndromes.6.1. Implications for clinicians and policymakers
Although our hospital is one of Europe’s largest cardiovascular
centres, covering a population of around six million people, pooling
of data internationally will be important to accurately determine
changes in emergency primary PCI activity and thus model for
excess indirect harms due to COVID. A global survey [20] has
reported the perception of substantially reduced STEMI activity
and delays to treatment amongst those who responded, however
it will be critical to marry perceptions with actual changes. A care-
ful balance is needed to manage cardiac patients and those with
other specialised conditions, in the next phase of the COVID-19
pandemic. Whilst they are at an increased risk of severe disease
due to COVID-19 itself, it is also the case that they are at elevated
risk of mortality and morbidity from their underlying conditions,4
particularly if they do not seek or receive care in a timely manner
or even at all.
The design of any prediction model benefits from the use of
rich, high quality data. When this can be directed to offer bespoke
modelling relevant to individual patient groups, better decisions
can be made by our profession and our patients alike, using
nuanced analyses of the risk–benefit ratio of emergency and urgent
elective treatments.7. Conclusion
The emergency activity of a high-volume centre in the UK was
significantly reduced for primary PCI in STEMI during the peak of
the first wave of COVID-19. We cautiously modelled the excess
indirect cardiovascular morbidity and mortality related to acute
coronary syndromes. Our data can be used as an exemplar to help
future modelling within cardiovascular and broader workstreams
to refine aggregate and population level estimates of the impact
of COVID-19.
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